<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR522.html">Part 522
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 522.1850  Polysulfated glycosaminoglycan.
                            </h3>
                            <p class="depth1"><em>(a)</em> Specifications. (1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.</p><p class="depth2"><em>(1)</em> Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.</p><p class="depth2"><em>(2)</em> Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.</p><p class="depth1"><em>(b)</em> Sponsor. See No. 010797 in Sec. 510.600(c) of this chapter.</p><p class="depth1"><em>(c)</em> Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth1"><em>(d)</em> Conditions of use--(1) Horses--(i) Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.</p><p class="depth2"><em>(1)</em> Horses--(i) Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.</p><p class="depth3"><em>(i)</em> Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.</p><p class="depth3"><em>(ii)</em> Amount--(A) Intra-articular use (carpal): 250 mg once a week for 5 weeks.</p><p class="depth4"><em>(A)</em> Intra-articular use (carpal): 250 mg once a week for 5 weeks.</p><p class="depth4"><em>(B)</em> Intramuscular use (carpal and hock): 500 mg every 4 days for 28 days.</p><p class="depth3"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption.</p><p class="depth2"><em>(2)</em> Dogs--(i) Indications for use. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.</p><p class="depth3"><em>(i)</em> Indications for use. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.</p><p class="depth3"><em>(ii)</em> Amount. 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).
[72 FR 56896, Oct. 5, 2007, as amended at 74 FR 67816, Dec. 21, 2009]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
